Geoffrey M. Parker
CIK 1491874 · CHIEF FINANCIAL OFFICER · last filed 2026-05-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.02M
Companies
9
Total Filings
126
Lifetime Open-Market Net
$5.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRGO | Director | 58,589 | $10.99 | $643.9K | $1.63M | 31 | 2026-05-15 |
| ALLO | CHIEF FINANCIAL OFFICER | 1,252,795 | $1.90 | $2.38M | -$95.3K | 9 | 2026-02-04 |
| Better Therapeutics, Inc. (BTTX) Delisted | Director | 1,085,138 | $0.04 | $48.4K | $917.2K | 9 | 2023-12-20 |
| CCXI | Director | 0 | $10.22 | $0 | -$2.61M | 25 | 2022-10-24 |
| Tricida, Inc. (TCDA) Delisted | COO, CFO and EVP | 118,617 | $0.11 | $12.8K | $4.25M | 17 | 2022-03-02 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 955 | — | — | $0 | 4 | 2019-06-18 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 13,480 | $18.62 | $251.0K | $58.2K | 6 | 2017-06-02 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Executive Vice President & CFO | 104,840 | $10.19 | $1.07M | $1.67M | 20 | 2015-03-23 |
| GENOPTIX INC (GXDX) Delisted | Director | 4,167 | — | — | $0 | 4 | 2011-03-01 |
Recent Filings · Page 3 of 13
126 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-17 | ALLO | Grant (A) | +790,000 | $0 | EDGAR |
| 2023-07-31 | Better Therapeutics, Inc. (BTTX) Delisted | Buy (P) | +685,025 | $500.0K | EDGAR |
| 2023-06-14 | PRGO | Buy (P) | +10,000 | $330.6K | EDGAR |
| 2023-06-09 | Better Therapeutics, Inc. (BTTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | PRGO | Mixed | +4,044 | $132.9K | EDGAR |
| 2023-05-17 | PRGO | Grant (A) | — | $0 | EDGAR |
| 2023-04-12 | Better Therapeutics, Inc. (BTTX) Delisted | Buy (P) | +303,030 | $250.0K | EDGAR |
| 2023-03-07 | PRGO | Buy (P) | +5,000 | $190.3K | EDGAR |
| 2022-10-24 | CCXI | Disp (D) | −134,073 | $0 | EDGAR |
| 2022-06-14 | Better Therapeutics, Inc. (BTTX) Delisted | Buy (P) | +25,000 | $36.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.